2 May 2022 - The Government granted health insurance benefits to the combination therapy of Tecentriq and Avastin to treat ...
2 May 2022 - Gilead Science Korea said its hepatitis B treatment Vemlidy (tenofovir alafenamide) started receiving expanded health insurance ...
25 April 2022 - The Ministry of Health and Welfare’s Health Insurance Policy Review Committee is scheduled to hold a ...
14 April 2022 - Roche’s new spinal muscular atrophy oral treatment Evrysdi (risdiplam) proved the benefit of convenience and cost ...
8 April 2022 - Pfizer’s Lorviqua (lorlatinib), a third generation anaplastic lymphoma kinase (ALK) targeted therapy, passed the review for ...
7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer ...
5 April 2022 - The National Human Rights Commission of Korea welcomed the recent reimbursement of CAR-T cell therapy Kymriah ...
30 March 2022 - Roche Korea and the Government failed to reach an agreement over the reimbursement rate of Tecentriq ...
23 March 2022 - The South Korean Government has approved the emergency use of anti-COVID-19 pill Lagevrio, the Ministry of ...
21 March 2022 - The Government will introduce the oral antiviral medicine Lagevrio for 100,000 patients this week while seeking ...
17 March 2022 - MSD’s Keytruda (pembrolizumab) became reimbursable for the first-line treatment of non-small-cell lung cancer in March, enabling ...
15 March 2022 - Drained by dragging price negotiations between Novartis and the Government for breakthrough cancer treatment Kymriah (tisagenlecleucel), ...
10 March 2022 - Roche is negotiating with the government over the reimbursement price of Tecentriq (atezolizumab), which passed the ...
4 March 2022 - AstraZeneca’s Koselugo (selumetinib), the first rare disease treatment approved in Korea through an accelerated review due ...
22 February 2022 - MSD’s anti-PD-1 immunotherapy Keytruda (pembrolizumab) obtained health insurance benefits five years after winning marketing approval to ...